These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 25908036)

  • 1. Neoadjuvant chemotherapy in locally advanced gastric cancer: what to avoid. Preliminary analysis of a consecutive series of patients.
    Rausei S; Lianos GD; Proserpio I; Ruspi L; Galli F; Frattini F; Mangano A; Rovera F; Boni L; Roukos DH; Pinotti G; Dionigi G
    Tumori; 2015; 101(5):511-6. PubMed ID: 25908036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy.
    Persiani R; D'Ugo D; Rausei S; Sermoneta D; Barone C; Pozzo C; Ricci R; La Torre G; Picciocchi A
    J Surg Oncol; 2005 Mar; 89(4):227-36; discussion 237-8. PubMed ID: 15726615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer.
    Brenner B; Shah MA; Karpeh MS; Gonen M; Brennan MF; Coit DG; Klimstra DS; Tang LH; Kelsen DP
    Ann Oncol; 2006 Sep; 17(9):1404-11. PubMed ID: 16788003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
    Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
    Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study.
    Ott K; Sendler A; Becker K; Dittler HJ; Helmberger H; Busch R; Kollmannsberger C; Siewert JR; Fink U
    Gastric Cancer; 2003; 6(3):159-67. PubMed ID: 14520529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer.
    Li ZY; Koh CE; Bu ZD; Wu AW; Zhang LH; Wu XJ; Wu Q; Zong XL; Ren H; Tang L; Zhang XP; Li JY; Hu Y; Shen L; Ji JF
    J Surg Oncol; 2012 Jun; 105(8):793-9. PubMed ID: 22189752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epirubicin, oxaliplatin, and capectabine is just as "MAGIC"al as epirubicin, cisplatin, and fluorouracil perioperative chemotherapy for resectable locally advanced gastro-oesophageal cancer.
    Sirohi B; Barreto SG; Singh A; Batra S; Mittra A; Rastogia S; Ramadwar M; Shetty N; Goel M; Shrikhande SV
    J Cancer Res Ther; 2014; 10(4):866-70. PubMed ID: 25579520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer.
    Martin-Romano P; Sola JJ; Diaz-Gonzalez JA; Chopitea A; Iragorri Y; Martínez-Regueira F; Ponz-Sarvise M; Arbea L; Subtil JC; Cano D; Ceniceros L; Legaspi J; Hernandez JL; Rodríguez J
    Br J Cancer; 2016 Sep; 115(6):655-63. PubMed ID: 27537382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer.
    Kim MS; Lim JS; Hyung WJ; Lee YC; Rha SY; Keum KC; Koom WS
    World J Gastroenterol; 2015 Mar; 21(9):2711-8. PubMed ID: 25759540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial.
    Fazio N; Biffi R; Maibach R; Hayoz S; Thierstein S; Brauchli P; Bernhard J; Stupp R; Andreoni B; Renne G; Crosta C; Morant R; Chiappa A; Luca F; Zampino MG; Huber O; Goldhirsch A; de Braud F; Roth AD; ;
    Ann Oncol; 2016 Apr; 27(4):668-73. PubMed ID: 26712905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neoadjuvant chemotherapy for locally advanced gastric cancer].
    Kalmár K; Cseke L; Káposztás Z; Horváth G; Varga E
    Magy Seb; 2003 Oct; 56(5):177-84. PubMed ID: 15022621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of neoadjuvant chemotherapy with PELF-protocoll versus surgery alone in the treatment of advanced gastric carcinoma.
    Ruf C; Thomusch O; Goos M; Makowiec F; Illerhaus G; Ruf G
    BMC Surg; 2014 Jan; 14():5. PubMed ID: 24461063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response.
    Ajani JA; Winter K; Okawara GS; Donohue JH; Pisters PW; Crane CH; Greskovich JF; Anne PR; Bradley JD; Willett C; Rich TA
    J Clin Oncol; 2006 Aug; 24(24):3953-8. PubMed ID: 16921048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma.
    Zhang XL; Shi HJ; Cui SZ; Tang YQ; Ba MC
    Eur J Surg Oncol; 2011 Jun; 37(6):466-72. PubMed ID: 21414740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemotherapy versus surgery alone for locally advanced gastric cancer: a retrospective comparative study.
    Wang LB; Shen JG; Xu CY; Chen WJ; Song XY; Yuan XM
    Hepatogastroenterology; 2008; 55(86-87):1895-8. PubMed ID: 19102417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No survival benefit from postoperative adjuvant chemotherapy after D2 radical resection for the patients with stage II gastric cancer.
    Chen S; Chen YB; Zhou ZW; Li W; Sun XW; Xu DZ; Li YF; Guan YX; Feng XY; Zhan YQ
    Am J Clin Oncol; 2011 Jun; 34(3):309-13. PubMed ID: 20838324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer.
    Barone C; Cassano A; Pozzo C; D'Ugo D; Schinzari G; Persiani R; Basso M; Brunetti IM; Longo R; Picciocchi A
    Oncology; 2004; 67(1):48-53. PubMed ID: 15459495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of neoadjuvant and adjuvant chemotherapy with 5-fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma.
    Solomon N; Mezentsev D; Reis I; Lima M; Rios J; Avisar E; Franceschi D; Livingstone A; Podolsky L; Ardalan B
    Jpn J Clin Oncol; 2011 Apr; 41(4):469-76. PubMed ID: 21258083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy.
    Badgwell B; Blum M; Estrella J; Chiang YJ; Das P; Matamoros A; Fournier K; Mansfield P; Ajani J
    J Am Coll Surg; 2015 Jul; 221(1):83-90. PubMed ID: 26002780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.